ANL
Adlai NortyeANL
ANL
$1.96
8.79%
Market Cap: $72.3M
About: Adlai Nortye Ltd is a clinical-stage biotechnology company focused on the discovery and development of cancer therapies for patients across the spectrum of tumor types. The company has a robust pipeline of drug candidates which includes buparlisib (AN2025), palupiprant (AN0025), and AN4005 in the clinical stage, and AN8025, AN9025, and AN1025 in the preclinical stage.
Employees: 127
0
Funds holding %
of 6,710 funds
–
Analysts bullish %
Fund manager confidence
Based on 2024 Q2 SEC filings by fund managers ($100M+ AUM)
0% more funds holding
Funds holding: 3 [Q1] → 3 (+0) [Q2]
0% less ownership
Funds ownership: 0.06% [Q1] → 0.06% (-0%) [Q2]
0% more repeat investments, than reductions
Existing positions increased: 1 | Existing positions reduced: 1
62% less capital invested
Capital invested by funds: $514K [Q1] → $197K (-$317K) [Q2]
Research analyst outlook
1 Wall Street Analyst provided 1 year price targets over the past 3 months
Low target
$9
359%
upside
Avg. target
$9
359%
upside
High target
$9
359%
upside
1 analyst rating
1 positive
100%
0 neutral
0%
0 negative
0%
HC Wainwright & Co. Joseph Pantginis 36% 1-year accuracy 90 / 249 met price target | 359%upside $9 | Buy Initiated | 4 Sept 2024 |